Zymeworks (ZYME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Executive summary
Annual meeting scheduled for December 30, 2025, at 9:00 a.m. Pacific Time, to be held virtually via the Internet.
Proxy materials, including the Notice, Proxy Statement, and Annual Report on Form 10-K, are available online for review and voting.
Shareholders are encouraged to review all proxy materials before voting and can request paper or email copies at no cost.
Voting matters and shareholder proposals
Election of three directors: Carlos Campoy, Alessandra Cesano, and Robert E. Landry.
Advisory vote on the compensation of named executive officers.
Ratification of KPMG LLP as auditors for the year ending December 31, 2025.
Board recommends voting FOR all nominees and proposals.
Board of directors and corporate governance
Board of Directors has nominated three individuals for election at the annual meeting.
Recommendations and voting instructions are provided to ensure shareholder participation.
Latest events from Zymeworks
- Strategy targets royalty growth, $440M milestones, and $125M share buyback for long-term value.ZYME
Investor Update9 Jul 2026 - Zanidatamab advances globally as cash of $395.9M supports a strong pipeline and narrowed losses.ZYME
Q2 20248 Jul 2026 - Q1 2025 revenue surged 171% on milestones; cash runway extends into 2H-2027.ZYME
Q1 20258 Jul 2026 - Acquisition adds YUPELRI®, diversified assets, and tax benefits, boosting cash flow and value.ZYME
M&A announcement29 Jun 2026 - Zanidatamab nears approval as pipeline assets advance and R&D shifts to novel multi-specifics.ZYME
Jefferies Global Healthcare Conference 20264 Jun 2026 - Annual meeting to vote on directors, executive pay, auditor, and highlight ESG and governance.ZYME
Proxy filing18 May 2026 - Key votes include director elections, executive pay, and auditor ratification at the 2024 meeting.ZYME
Proxy filing18 May 2026 - Board recommends approval of all proposals, with strong focus on governance and performance-based pay.ZYME
Proxy filing18 May 2026 - Q3 revenue up 73% on milestone and royalty gains, with narrowed net loss and strong cash runway.ZYME
Q3 202518 May 2026